Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Topical Retinoids Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 355-A

    Initial Prior Authorization Topical Retinoids

    Customize your policy alerts

    Sign up for cvs_caremark Policy 355-A alerts

    Get alerted when Policy 355-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Initial and continuation prior authorization for prescription topical retinoid products, including tretinoin and clindamycin/tretinoin products, for acne vulgaris and keratosis follicularis (Darier disease).

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Topical Retinoids
    Policy CodePolicy 355-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionThe provider must establish that the patient has a diagnosis of acne vulgaris or keratosis follicularis for authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8Brand/generic product entries referenced
    2Covered diagnostic indications
    4 monthsInitial therapy approval duration
    36 monthsContinuation therapy approval duration
    9+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age for Altreno and Twyneo
    12+Minimum age for Ziana and clindamycin/tretinoin gel

    Coverage Criteria

    Initial coverage - acne vulgaris

    Covered when the patient has the specified diagnosis.

    Acne vulgaris

    • The patient has a diagnosis of acne vulgaris.

    Initial coverage - keratosis follicularis

    Covered when the patient has the specified diagnosis.

    Keratosis follicularis

    • The patient has a diagnosis of keratosis follicularis (Darier's disease, Darier-White disease).

    Continuation therapy - acne vulgaris

    Continuation may be authorized when the diagnosis is acne vulgaris and the following criterion is met.

    Acne vulgaris continuation

    • The patient has a diagnosis of acne vulgaris.
    • The patient has achieved or maintained a positive clinical response as evidenced by improvement, such as reduction in number of lesions or patient satisfaction.Positive clinical response with improvement

      Examples include reduction in number of lesions or patient satisfaction.

    Continuation therapy - keratosis follicularis

    Continuation may be authorized when the diagnosis is keratosis follicularis and the following criterion is met.

    Keratosis follicularis continuation

    • The patient has a diagnosis of keratosis follicularis (Darier's disease, Darier-White disease).
    • The patient has achieved or maintained a positive clinical response as evidenced by improvement.Positive clinical response with improvement

    Provider Documentation Requirements

    Documentation Required

    Document acne vulgaris diagnosis

    Establish that the patient has a diagnosis of acne vulgaris when requesting authorization for topical retinoid therapy.

    Documentation Required

    Document keratosis follicularis diagnosis

    Establish that the patient has a diagnosis of keratosis follicularis for authorization. The diagnosis may also be documented as Darier's disease or Darier-White disease.

    Clinical Background

    Topical retinoids are used for the topical treatment of acne vulgaris. The policy also recognizes keratosis follicularis, also known as Darier’s disease or Darier-White disease, as a compendial use. FDA-approved acne age specifications vary by product: Altreno and Twyneo are indicated for patients 9 years of age and older, while Ziana and clindamycin phosphate/tretinoin gel are indicated for patients 12 years or older.

    Definitions

    Keratosis follicularis
    DefinitionKeratosis follicularis is a covered compendial indication under this policy.
    Alternate namesDarier's disease; Darier-White disease.
    Coverage requirementAuthorization may be granted when the patient has a diagnosis of keratosis follicularis.

    Initial Therapy Criteria

    Initial therapy - acne vulgaris

    Initial authorization may be granted for acne vulgaris.

    Acne vulgaris diagnosis

    • The patient has a diagnosis of acne vulgaris.

    Initial therapy - keratosis follicularis

    Initial authorization may be granted for keratosis follicularis.

    Keratosis follicularis diagnosis

    • The patient has a diagnosis of keratosis follicularis (Darier's disease, Darier-White disease).

    Continuation Therapy Criteria

    Acne vulgaris continuation

    For acne vulgaris, continuation authorization may be granted when the patient has achieved or maintained a positive clinical response.

    Acne vulgaris response

    • The patient has achieved or maintained a positive clinical response as evidenced by improvement, such as reduction in number of lesions or patient satisfaction.Positive clinical response with improvement

    Keratosis follicularis continuation

    For keratosis follicularis, continuation authorization may be granted when the patient has achieved or maintained a positive clinical response.

    Keratosis follicularis response

    • The patient has achieved or maintained a positive clinical response as evidenced by improvement.
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Topical Retinoids
    Policy CodePolicy 355-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionThe provider must establish that the patient has a diagnosis of acne vulgaris or keratosis follicularis for authorization.
    SourceLink
    On This Page
    Coverage CriteriaProvider Documentation RequirementsClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy Criteria
    Positive clinical response with improvement